Evidence map›Paper›PMID 42297998›Full record

ReviewMolecular genetics and genomics : MGG2026

Integrating HTS and CRISPR/Cas for next-generation nucleic and non-nucleic acid diagnostics.

Manoj Kumar Mishra, Sagar Pamu, Prathap Madeswara Guptha, Murugesan Vanangamudi, Sathish Kumar Mittapalli, Pragyandip Parthasarathi Dash, Vanrajsinh Thakor, Palakurthi Yanadaiah, Sazal Patyar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manoj Kumar MishraDepartment of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, 474005, Madhya Pradesh, India.
Sagar PamuDepartment of Pharmacy Practice, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, Gujarat, India. dr.sagar@live.com.
Prathap Madeswara GupthaDepartment of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research (Deemed to be University), Andhra Pradesh, 522213, Guntur, India.
Murugesan VanangamudiDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Research, GLA University, Mathura, 281406, Uttar Pradesh, India.
Sathish Kumar MittapalliDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Parul Institute of Pharmaceutical Education and Research, Parul University, Vadodara, 391760, Gujarat, India.
Pragyandip Parthasarathi DashDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Science, Faculty of Pharmacy, Parul University, Vadodara, 391760, Gujarat, India.
Vanrajsinh ThakorDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, Gujarat, India.
Palakurthi YanadaiahDepartment of Pharmacy Practice, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India.
Sazal PatyarDepartment of Pharmacology, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synergy between HTS and CRISPR/Cas is changing how genes, biomarkers, and diseases are studied. Very useful due to the ability to scan entire molecular libraries in a single assay and its extreme rapidity. CRISPR/Cas systems, however, are crucial for achieving control and specificity, properties essential for precise genetic editing and targeted detection. HTS could be combined with CRISPR in two ways: HTS would expand the search space, and CRISPR would narrow it. This perspective highlights recent advances in which both platforms have been used together - for example, to find genetic variants and molecular markers in cancer, infectious diseases, and even biosensors to track the environment and metabolism. We discuss technical advances as well as practical issues that make the use of CRISPR/Cas more challenging in the clinical environment, including off-target activity, reproducibility, and the increasing complexity and dimensionality of data.

Indexed as

CRISPR-Cas SystemsHigh-Throughput Nucleotide SequencingHigh-Throughput Screening AssaysGene EditingHumansBioinformaticsCRISPR/CasFunctional genomicsGenomic biomarkersHigh-throughput screeningPrecision diagnostics

Identifiers

PMID42297998

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.